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The chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA) have
been recently much focused as independent risks for cardiovascular disease. Furthermore,
the complication of both has a worse prognosis compared with patients with only one of these
diseases. However, the details of the underlying mechanisms of this worsened prognosis have
not been clear. The cross-sectional study was conducted to examine whether the overlap of
COPD augment the increase in arterial stiffness in subjects with OSA. If so, we examined
the exaggeration of nocturnal hypoxemia and its related inflammation are related to this
augmentation of increased arterial stiffness. In 524 male subjects with OSA diagnosed by poly-
somnography (apneaehypopnea index >5/h) (52  14 years old), the forced expiratory volume
at 1 s/the forced vital capacity (FEV1/FVC) ratio, brachial-ankle pulse wave velocity (baPWV),
blood C-reactive protein (CRP) and B-natriuretic peptide (BNP) levels were measured. The
prevalence rate of COPD was 12% in this study subjects. Plasma BNP levels and the crude
(median value, 17.2 vs. 14.1 m/s, p < 0.01) and adjusted value of baPWV were significantly
higher in subjects with overlap syndrome than in those with OSA alone. However, parameters
of nocturnal hypoxemia and serum CRP levels were similar between both groups. Thus, the
overlap of COPD in patients with OSA augments increase in arterial stiffness without the exag-
geration of nocturnal hypoxemia and inflammation. Even so, this augmentation may partially
contribute to the increased cardiovascular risk in the overlap syndrome.
ª 2012 Elsevier Ltd. All rights reserved.3342 6111; fax: þ81 3 3342 4820.
ed.ac.jp (H. Tomiyama).
2 Elsevier Ltd. All rights reserved.
Figure 1 Study protocol. OSA Z obstructive sleep apnea;
AHI Z apneaehypopnea index; CRNZ serum creatinine level;
CRP Z serum C-reactive protein level; FVC Z forced vital
capacity; PWV Z pulse wave velocity.
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Several studies have demonstrated that increased arterial
stiffness acts as an independent risk factor for cardiovas-
cular disease via several mechanisms.1e3 Obstructive sleep
apnea (OSA) has also drawn much attention as an inde-
pendent risk factor for cardiovascular disease.4,5 In
patients with OSA, arterial stiffness is increased6e8 and
therefore, this increase is thought to have some contribu-
tion to the increased cardiovascular risk in these patients.
On the other hand, arterial stiffness is also increased in
patients with chronic obstructive pulmonary disease
(COPD), an independent risk factor for cardiovascular
disease.9 Previous studies have suggested that the preva-
lence of COPD in patients with OSA was, respectively, of
11%10 and 14%,11 therefore, overlap coexistence of the two
conditions is not rare in clinical settings. Patients with the
overlap syndrome have a worse prognosis as compared with
patients with only one of these diseases.12,13 While the
underlying mechanisms of this worsened prognosis have not
yet been fully clarified, it is possible that accelerated
arterial stiffening contributes to the overlap-related wors-
ening of the prognosis in the overlap syndrome.
The present cross-sectional study was conducted to
examine whether the overlap of COPD might augment the
increased arterial stiffness in subjects with OSA. If so, we
examined the exaggeration of nocturnal hypoxemia and its
related inflammation are related to this augmentation of
increased arterial stiffness.Methods
Study patients
We evaluated all eligible patients from 756 consecutive
patients who underwent overnight polysomnography (PSG)
at Tokyo Medical University Hospital from November 2004
to April 2009. The exclusion criteria were: women (because
of the small number of study subjects) (nZ 121), AHI <5.0
(n Z 11), presence of cardiovascular disease {ischemic
heart disease, valvular heart disease, cardiomyopathy,
atrial fibrillation, stroke, arteriosclerosis obliterans, aortic
aneurysm, pulmonary embolism, and a left ventricular
ejection fraction (LVEF) of less than 40%} (n Z 72), renal
insufficiency (serum creatinine level >176.8 mmol/L)
(nZ 8), serum C-reactive protein level >1.0 mg/L (nZ 8),
and subjects with restrictive pulmonary disease {percent
predicted forced vital capacity (FVC) <80%} (n Z 12).
Finally, 524 patients were successfully entered in the final
analysis (Fig. 1). The study was conducted with the
approval of the Ethics Committee of Tokyo Medical
University, and written informed consent was obtained
from each of the subjects prior to their participation in the
study.
Sleep study
Overnight, fully-attended PSG monitoring was performed
with the Alice 4 Sleep System (Respironics, Inc., Murrys-
ville, PA) in the sleep laboratory. The sleep stages weremonitored by electroencephalography, electrooculography
and electromyography, according to standard criteria,14e16
and arousals were defined according to the standard
criteria of the American Academy of Sleep Medicine.14e16
Oronasal airflow was measured with a thermistor, thor-
acoabdominal movements were monitored with a strain
gauge, and the oxyhemoglobin saturation (SpO2) in the
blood was monitored by pulse oximetry. Then, the mean
nocturnal oxygen transcutaneous saturation (meanSpO2),
minimal nocturnal oxygen transcutaneous saturation (min-
SpO2), and recording time spent at nocturnal oxygen
transcutaneous saturation <90% (timeSpO2 <90%) were
obtained as markers of nocturnal hypoxemia. The respira-
tory events and sleep stage were scored manually.14e16
Apnea was defined as cessation of oronasal airflow for
10 s or more, and hypopnea was defined as a 50% or greater
decrease in oronasal airflow lasting for more than 10 s
associated with a 3% or greater decrease in arterial oxygen
saturation relative to the baseline level. Obstructive
apnea/hypopnea was defined as the significant apnea/
hypopnea in the presence of thoraco-abdominal effort, and
central apnea/hypopnea was defined as significant apnea/
hypopnea in the absence of oronasal air flow or thoraco-
abdominal effort.14e16 The apneaehypopnea index (AHI)
was calculated as the total number of apnea and hypopnea
episodes per hour of sleep. Patients were defined as having
OSA when the obstructive component was dominant and
the AHI was 5 per hour. The severity of OSA was classified
according the criteria of the American Academy of Sleep
Medicine (i.e., AHI 5e14 per hour Z mild; 15e30 per
hour Z moderate; 30 per hour Z severe).14e16
Pulmonary function
Pulmonary function was measured with a volume-
displacement, water-sealed spirometer (SP-750, Fukuda
Co. Ltd, Tokyo, Japan), based on a forced vital capacity
maneuver, in which the subject was requested to exhale
the maximal volume of air during a forced expiratory
maneuver starting from a position of full inspiration and
ending at complete expiration. The forced expiratory
Arterial stiffness in overlap syndrome 1337volume at 1 s (FEV1), forced vital capacity (FVC) and FEV1/
FVC ratio were examined. The coefficient of variation of
the FEV1/FVC ratio was 2.9% at our institute. The
measurements were conducted by trained technicians.
Overlap syndrome was defined according to McNicholas’s
report.17 An FEV1/FVC ratio of >70% plus FVC >80% was
defined as pulmonary function within the normal range.
Overlap syndrome was defined as AHI 5 per hour with an
FEV1/FVC ratio of 70% plus FVC >80%. On the other hand,
the severity of COPD was graded as follows: mild Z FEV1
>80% predicted; moderate Z FEV1 50e79% predicted;
severe Z FEV1 <50% predicted.
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Echocardiogram
M-mode echocardiograms were obtained by two-
dimensional echocardiography using an echocardiography
instrument equipped with a 3.0-MHz to 5.0-MHz transducer.
The mean of two M-mode measurements obtained by two
investigators was used. The left ventricular mass was
calculated by Deveroux’s method.19 The left ventricular
mass index (LVMI) was estimated as the left ventricular
mass divided by the body surface area. Left ventricular
systolic and diastolic volumes and LVEF were derived from
the M-mode images, according to standard criteria.20
Pulsed Doppler measurements of the left ventricular dia-
stolic inflow were obtained by two-dimensional echo-guid-
ance. Briefly, the left ventricular diastolic filling pattern
was recorded from the apical transducer position in
patients in the partial left lateral decubitus position during
expiratory apnea, the sample volume situated between the
mitral leaflet tips. The peak velocity of early rapid filling (E
velocity) and the peak velocity of atrial filling (A velocity)
were recorded, and the E/A ratio and deceleration time
(DCT) were calculated as the interval from the E-wave peak
to the decline of the velocity to the baseline values
obtained from 3 consecutive cardiac cycles.
Brachial-ankle pulse wave velocity
The brachial-ankle PWV (baPWV) was measured using
a volume-plethysmographic apparatus (Form/ABI, Colin Co.
Ltd., Komaki, Japan), in accordance with a previously
described methodology.21,22 Briefly, electrocardiographic
electrodes were placed on both wrists, and a microphone
for the phonocardiogram was attached to the left chest.
Electrocardiograms and phonocardiograms were used to
provide timing markers for the device. Occlusion cuffs,
which were connected to both the plethysmographic and
oscillometric sensors, were tied around both the upper
arms and ankles while the subjects lay in the supine posi-
tion. The brachial and post-tibial arterial pressures were
measured by the oscillometric sensor. The brachial and
post-tibial arterial pressure waveforms determined by the
plethysmographic sensor and recorded for 10 s were stored.
The measurements were conducted after the subjects had
rested for at least 5 min in the supine position, in an air-
conditioned room24e26 earmarked exclusively for this
purpose. The blood pressure determined by the oscillo-
metric sensor and the heart rate was simultaneously
obtained during measurement of the baPWV.Laboratory measurements
The serum levels of total cholesterol (TC), high-density
lipoprotein cholesterol (HDL), triglycerides (TG), creatinine
(CRN), and the fasting plasma glucose (FPG) were measured
enzymatically in blood samples obtained from the subjects
after they had fasted overnight.
Statistical analysis
Since the deviation of AHI and FEV1/FVC ratio were skewed,
the values of these variables were log-transformed for the
analysis in this study. The normality of the distribution of
the variables was assessed by the KolmogoroveSmirnov
test. Then, the variables that showed normal distribution
were represented as mean  SD, and those that did not
show normal distribution were represented as the median
(25the75th percentile) values, as shown in Table 1.
The relationships of the baPWV with other variables
were assessed by univariate linear regression analysis and
multivariate linear regression analysis. In these analyses,
the variables not showing normal distribution were log-
transformed. For the adjustments, a Basic Adjustment
Model was used, with the smoking status (non- or past
smoker Z 0, current smoker Z 1), age, TC, log-
transformed variables (body mass index, mean blood pres-
sure, heart rate, HDL, TG, CRN, FPG and AHI) and history/
no history of medication for hypertension, diabetes melli-
tus and/or dyslipidemia (this factor was assigned a score of
1 for the presence of a history of medication and 0 for the
absence of a history of medication) as the covariates. Thus,
the details of the drug types prescribed were not consid-
ered and the adjustment was applied for the drug classes as
a composite.
For assessment of the differences in the status of each
variable among the groups, KruskaleWallis test for contin-
uous variables and Pearson’s chi-squared test for categor-
ical variables were applied. Furthermore, for assessment of
the differences in the status of the baPWV among the
groups, a general linear model (GLM) analysis with adjust-
ments was applied. Covariates that were adjusted for were
similar to those mentioned for the multivariate linear
regression analyses. All the analyses were conducted using
the SPSS software for Windows, version 11.0J (SPSS, Chi-
cago, IL); P values <0.05 were considered to denote
statistical significance.
Results
The KolmogoroveSmirnov test demonstrated that only age
and TC were normally distributed, while other variables
such as the baPWV, AHI, FEV1/FVC ratio, and FEV1 were not
normally distributed showed skewed distribution. The
prevalence rate of COPD was 12% in this study subjects. The
clinical characteristics of the study subjects with OSA alone
and those with overlap syndrome are described in Table 1.
The age and serum BNP levels were higher and the BMI and
ESS were lower in subjects with overlap syndrome than in
those with OSA alone, however, the serum CRP levels was
similar between the two groups (Table 1). In the entire
study population, 57% (296/524 men) were categorized as
Table 1 Clinical characteristics of the patients with OSA alone and overlap syndrome.
OSA alone
n Z 461(88%)
Overlap
n Z 63 (12%)
P value
Age (yr) 48.6  12.8 63.9  11.7 <0.01
BMI (kg/m2) 26.0 (23.7e28.5) 24.8 (23.4e26.1) 0.04
Current Smoker, n (%) 201 (44) 29 (46) 0.40
SBP (mmHg) 126 (117e134) 127 (119e137) 0.46
DBP (mmHg) 76 (69e82) 76 (70e84) 0.97
TC (mmol/L) 5.3  0.9 5.1  0.8 0.13
HDL (mmol/L) 1.2 (1.1e1.5) 1.2 (1.1e1.6) 0.91
TG (mmol/L) 1.8 (1.3e2.5) 1.5 (1.1e2.2) 0.10
FPG (mmol/L) 4.9 (4.5e5.5) 5.1 (4.7e5.6) 0.25
CRN (mmol/L) 72.3 (64.2e80.3) 74.0 (67.8e83.8) 0.16
BNP (pg/dl) 10.9 (5.3e20.8) 20.8 (9.7e57.0) <0.01
CRP (mg/dl) 0.06 (0.03e0.14) 0.07 (0.03e0.19) 0.32
ESS 9.0 (6.0e13.0) 7.0 (4.5e11.0) <0.01
Medication, n (%)
Hypertension 37 (8) 6 (10) 0.63
Diabetes mellitus 32 (7) 3 (5) 0.79
Dyslipidemia 73 (16) 16 (25) 0.07
FEV1/FVC ratio (%) 80.1 (76.7e84.0) 66.5 (63.1e68.7) <0.01
FEV1 (% predicted) 90.7 (84.8e98.6) 79.9 (68.4e90.4) <0.01
Severity of COPD, n (%)
Mild 34 (54)
Moderate 27 (43)
Severe 2 (3)
LVEF (%) 67.0 (64.0e70.0) 67.0 (63.0e71.0) 0.12
FS (%) 37.0 (35.0e40.0) 37.0 (34.0e40.0) 0.25
LVMI (g/m2) 120.4 (108.1e139.2) 129.4 (111.9e141.5) 0.11
DCT (s) 195.0 (171.0e221.0) 220.0 (190.0e254.0) <0.01
E/A ratio 1.29 (1.07e1.50) 0.84 (0.65e1.01) <0.05
baPWV (m/s) 14.1 (12.8e15.8) 17.2 (14.1e19.5) <0.01
Abbreviations: OSA Z obstructive sleep apnea; Overlap Z patients with OSA and chronic obstructive pulmonary disease; BMI Z body
mass index; SBP Z systolic blood pressure; DBP Z diastolic blood pressure; TC Z total cholesterol; HDL Z serum high density lipo-
protein cholesterol; TG Z serum triglycerides; FPG Z fasting plasma glucose; CRN Z serum creatinine concentration; BNP Z B-type
natriuretic peptide; CRP Z serum C-reactive protein levels; ESS Z Epworth sleepiness scale; FEV1/FVC ratio, the forced expiratory
volume at 1 s (FEV1) and the forced vital capacity (FVC) ratio; COPDZ chronic obstructive pulmonary disease; LVEFZ left ventricular
ejection fraction; FSZ fractional shortening; LVMIZ left ventricular mass index; DCTZ deceleration time; E/AZ the peak velocity of
early rapid filling (E velocity)/the peak velocity of atrial filling (A velocity); baPWV Z brachial-ankle pulse wave velocity.
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overlap syndrome, most were categorized as having mild/
moderate COPD (Table 1). In sleep study, total sleep time,
sleep efficiency and stage 3/4 sleep% were lower in
subjects with overlap syndrome than in those with OSA
alone, but parameters of nocturnal hypoxemia were similar
between the two groups (Table 2).
In the present study, most of the subjects with overlap
syndrome had mild to moderate COPD, and only two
subjects had severe COPD.
In vascular function test, baPWV and DCT were signifi-
cantly higher and E/A ratio was significantly lower in
subjects with overlap syndrome than in those with OSA
alone. However, the LVEF, FS and LVMI were similar
between the two groups (Table 1). The difference in the
baPWV was significant even after the adjustments for the
covariates and AHI (the covariates are described in detail in
the statistics section) (Fig. 2).The log-transformed baPWV had a significant correlation
with log-transformed AHI (correlation co-efficient Z 0.21,
P < 0.01), log-transformed FEV1/FVC ratio (correlation co-
efficient Z 0.35, P < 0.01) and log-transformed FEV1
(correlation co-efficient Z 0.12, P < 0.01). The log-
transformed AHI and log-transformed FEV1/FVC ratio were
entered simultaneously into the multivariate linear regres-
sion analysis. Then, multivariate linear regression analysis
demonstrated a significant relation between the log-
transformed FEV1/FVC ratio and the log-transformed
baPWV, independent of the covariates and log-transformed
AHI (Table 3). When the log-transformed FEV1 (rather than
the log-transformed FEV1/FVC ratio) was entered in this
multivariate model, it was identified as a significant factor
influencing the baPWV (R-square Z 0.55; standardized
coefficientZ 0.094, P < 0.05). The log-transformed FEV1/
FVC ratio showed no significant correlation with log-
transformed AHI (correlation co-efficient Z 0.006,
Table 2 Sleep study.
OSA alone n Z 461 Overlap n Z 63 P value
AHI 33.7 (20.3e53.9) 30.9 (20.2e51.3) 0.18
meanSpO2, % 95.0 (94.0e96.0) 95.0 (93.0e96.0) 0.63
minSpO2, % 81.0 (74.0e86.0) 81.0 (77.0e86.0) 0.18
timeSpO2 <90%, % 1.7 (0.3e7.7) 2.1 (0.2e5.6) 0.13
Desaturation index 27.3 (13.1e47.7) 23.2 (11.3e43.5) 0.09
Total sleep time, min 451 (405e489) 428 (400e465) <0.01
Sleep efficiency, % 83.9 (76.1e88.9) 78.5 (70.8e86.2) <0.01
Stage 1 sleep, % 26.3 (17.5e38.2) 29.7 (22.2e36.8) 0.66
Stage 2 sleep, % 50.5 (42.0e57.7) 50.8 (43.1e55.5) 0.76
Stage 3/4 sleep, % 1.7 (0.1e5.5) 0.6 (0.0e3.4) <0.01
Stage REM sleep, % 18.2 (14.1e21.8) 17.4 (13.3e21.1) 0.38
Arousal index 36.8 (26.1e54.6) 38.2 (27.4e48.2) 0.09
Abbreviations: AHI Z apneaehypopnea index; meanSpO2 Z mean nocturnal oxyhemoglobin saturation; minSpO2 Z the minimal
nocturnal oxyhemoglobin saturation; timeSpO2 <90%Z recording time spent at nocturnal oxyhemoglobin saturation <90%; REMZ rapid
eye movement.
Arterial stiffness in overlap syndrome 1339P Z 0.89), the log-transformed minSpO2 (correlation
co-efficient Z 0.02, P Z 0.66), the log-transformed mean-
SpO2 (correlation co-efficient Z 0.06, P Z 0.20), the
log-transformed timeSpO2 <90% (correlation co-
efficient Z 0.07, P Z 0.10), or log-transformed serum CRP
levels (correlation co-efficient Z 0.01, P Z 0.75). Further-
more, these parameters of nocturnal hypoxemia were
similar between the two groups (Table 1).Discussion
The present study was conducted to evaluate the effect of
overlap by COPD on the rate of arterial stiffness in subjects
with OSA. OSA and COPD represent two of the most prev-
alent chronic respiratory disorders.10,12,13 Both disorders
are associated with increased arterial stiffness,6e9 but the
their interaction has not yet been clarified. In the present
study, a significant correlation was observed between the
FEV1/FVC ratio, a marker of pulmonary dysfunction,
17 and
the baPWV, independent of the AHI, a marker of the
severity of OSA14e16; the baPWV was significantly higher inFigure 2 Crude and adjusted values of the baPWV in subje
baPWV Z brachial-ankle pulse wave velocity; values are presente
status, age, TC, log-transformed variables (body mass index, mean
history of medication (hypertension, diabetes mellitus and dyslipidsubjects with overlap syndrome than in those with OSA
alone. Thus, while several studies have reported that OSA
itself increases arterial stiffness,6,7 the present study is the
first to suggest that overlap by COPD is one of the key
elements underlying the increase in arterial stiffness in
subjects with OSA.
In the present study, 12% of the study subjects with OSA
had COPD, and the prevalence rate was consistent with
previous reports.10,11 Overlap by COPD is not rare in patients
with OSA, and patients with the overlap syndrome have
a lower 5-year survival than patients with OSA alone.10,12,13
Arterial stiffness is thought to act as a cardiovascular risk
factor via causing increased cardiac afterload, impaired
coronary blood supply, increase in shear stress on the
vascular endothelium (i.e., direct atherogenic action),
microvascular damage, and so on.1e3 Increased cardiac
afterload elevates the serum levels of BNP and causes left
ventricular hypertrophy.23 We previously reported that
increase of arterial stiffness is associated with elevation of
the serum BNP levels in the general population.24 In the
present study, the serumlevelsof BNPwerehigher in subjects
with overlap syndrome than in those with OSA alone,cts with OSA alone and those with the overlap syndrome.
d as the median (25the75th percentile) values. The smoking
blood pressure, heart rate, HDL, TG, CRN, FPG and AHI) and
emia) were included in the model as the covariates.
Table 3 Univariate and multivariate linear regression analysis to access relationship with log-transformed baPWV.
Univariate Multivariate (R-square Z 0.57)
r P value Non-standardized co-efficient (95% CI) Standardized co-efficient P value
log FEV1/FVC ratio 0.35 <0.01 0.109 (0.193 to 0.025) 0.091 <0.05
log AHI 0.21 <0.01 0.007 (0.01e0.024) 0.029 0.40
Abbreviations: CI Z confidence interval.
As described in the footnote for Table 1; the smoking status, age, TC, log-transformed variables (body mass index, mean blood pressure,
heart rate, HDL, TG, CRN, FPG and AHI) and history/no history of medication for hypertension, diabetes mellitus and/or dyslipidemia as
the covariates.
1340 K. Shiina et al.although the LVMI was similar between the two groups. Thus,
the results of the present study suggest that augmented
increase in arterial stiffness in the overlap syndrome may
contribute, at least in part, to the overlap-related increase in
cardiovascular risk. Hypoxemia and inflammation can
increase arterial stiffness.9,17,25,26
Lacedonia et al.27 reported that patients with overlap
syndrome present a high percentage of neutrophils in
induced sputum like patients affected by COPD or OSA
alone, however, the serum CRP, a marker of inflammation,
was similar between the two groups. While it is known that
overlap by COPD produces greater sleep disturbance and
oxygen desaturation than OSA alone,28 nocturnal hypox-
emia was not exaggerated in the subjects with overlap
syndrome in the present study. One of the plausible reason
for this discrepancy might be that most of the present study
subjects with the overlap syndrome had only mild to
moderate COPD, and COPD of milder severity may not be
associated with worsened nocturnal hypoxemia. The
present study demonstrated that the overlap of OSA by such
mild/moderate COPD may be associated with accelerated
arterial stiffening without worsening of the nocturnal
hypoxemia and inflammation.
The present study had some limitations, as follows: 1.
Age and obesity are major determinants of increase in the
arterial stiffness.29,30 The age and BMI of the subjects with
the overlap syndrome were higher than those of the
subjects with OSA alone. However, since even after
adjustments for these covariates, the baPWV was higher in
subjects with the overlap syndrome than that in the
subjects with OSA alone, a longitudinal study is proposed to
confirm that overlap by COPD is an important determinant
of the progression of arterial stiffening in subjects with
OSA; 2. Some studies have reported gender differences in
the PWV,2,3,22 but the present study was conducted only in
male subjects; 3. Increased arterial stiffness is thought to
act as a risk for cardiovascular disease; while the baPWV
only reflects the stiffness of the large to middle-sized
arteries, it shows close correlation with the carotid-
femoral PWV, a gold standard for assessment of the large
arterial stiffness31; 4. In the present study, while the serum
BNP levels were higher in the patients with the overlap
syndrome, the LVMI was similar between two groups. It is
possible that the regression of LVMI by antihypertensive
medication has some influence on this absence of differ-
ence of the LVMI between the two groups; 5. We did not
evaluate whether mild/moderate COPD might predispose to
daytime hypoxemia in the present study.Conclusion
In patients with OSA, pulmonary dysfunction may be an
independent risk factor for increase in arterial stiffness.
Overlap by COPD (mostly mild to moderate COPD) in
patients with OSA augments the increase in arterial stiff-
ness without exaggerating nocturnal hypoxemia or inflam-
mation. This augmentation may partially contribute to the
increased cardiovascular risk in patients with the overlap
syndrome.Acknowledgment
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